Evidence map›Paper›PMID 35957154›Full record

ArticleNanomaterials (Basel, Switzerland)2022

Highly Efficient Blood Protein Analysis Using Membrane Purification Technique and Super-Hydrophobic SERS Platform for Precise Screening and Staging of Nasopharyngeal Carcinoma.

Jinyong Lin, Youliang Weng, Xueliang Lin, Sufang Qiu, Zufang Huang, Changbin Pan, Ying Li, Kien Voon Kong, Xianzeng Zhang, Shangyuan Feng

Open access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Flexible 3D Plasmonic Web Enables Remote Surface Enhanced Raman Spectroscopy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Jinyong LinKey Laboratory of OptoElectronic Science and Technology for Medicine, Ministry of Education, Fujian Provincial Key Laboratory for Photonics Technology, Fujian Normal University, Fuzhou 350007, China.
Youliang WengClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Xueliang LinFujian Provincial Key Laboratory for Advanced Micro-Nano Photonics Technology and Devices, Research Center for Photonics Technology, Quanzhou Normal University, Quanzhou 362046, China.
Sufang QiuClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.ORCID 0000-0001-7660-6955
Zufang HuangKey Laboratory of OptoElectronic Science and Technology for Medicine, Ministry of Education, Fujian Provincial Key Laboratory for Photonics Technology, Fujian Normal University, Fuzhou 350007, China.ORCID 0000-0001-8290-5281
Changbin PanKey Laboratory of OptoElectronic Science and Technology for Medicine, Ministry of Education, Fujian Provincial Key Laboratory for Photonics Technology, Fujian Normal University, Fuzhou 350007, China.
Ying LiClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Kien Voon KongDepartment of Chemistry, National Taiwan University, Taipei 10617, Taiwan.
Xianzeng ZhangKey Laboratory of OptoElectronic Science and Technology for Medicine, Ministry of Education, Fujian Provincial Key Laboratory for Photonics Technology, Fujian Normal University, Fuzhou 350007, China.
Shangyuan FengKey Laboratory of OptoElectronic Science and Technology for Medicine, Ministry of Education, Fujian Provincial Key Laboratory for Photonics Technology, Fujian Normal University, Fuzhou 350007, China.
Fujian Normal University · CNFujian Medical University · CNNational Taiwan University · TWQuanzhou Normal University · CN

Funding

Fujian Medical Innovation Project 2021CXA029Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy 2020Y2012National Clinical key Specialty Construction Program 2021National Natural Science Foundation of China 61975031, 11974077, and 11874006Natural Science Foundation of Fujian Province 2020J011121 and 2021Y0053Product-University Cooperation Project of Fujian Province 2020Y4006United Fujian Provincial Health and Education Project for Tackling the Key Research, China 2019-WJ-03
6 · The paper itself

Abstract

Early screening and precise staging are crucial for reducing mortality in patients with nasopharyngeal carcinoma (NPC). This study aimed to assess the performance of blood protein surface-enhanced Raman scattering (SERS) spectroscopy, combined with deep learning, for the precise detection of NPC. A highly efficient protein SERS analysis, based on a membrane purification technique and super-hydrophobic platform, was developed and applied to blood samples from 1164 subjects, including 225 healthy volunteers, 120 stage I, 249 stage II, 291 stage III, and 279 stage IV NPC patients. The proteins were rapidly purified from only 10 µL of blood plasma using the membrane purification technique. Then, the super-hydrophobic platform was prepared to pre-concentrate tiny amounts of proteins by forming a uniform deposition to provide repeatable SERS spectra. A total of 1164 high-quality protein SERS spectra were rapidly collected using a self-developed macro-Raman system. A convolutional neural network-based deep-learning algorithm was used to classify the spectra. An accuracy of 100% was achieved for distinguishing between the healthy and NPC groups, and accuracies of 96%, 96%, 100%, and 100% were found for the differential classification among the four NPC stages. This study demonstrated the great promise of SERS- and deep-learning-based blood protein testing for rapid, non-invasive, and precise screening and staging of NPC.

Indexed as

deep learningnasopharyngeal carcinomaprotein SERSsuper-hydrophobic platform

Identifiers

PMID35957154
PMCPMC9370769
OpenAlexW4292452142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.